Researchers are using new technologies to examine the levels of a specific molecule, called COMMD1 in hundreds of human colorectal cancers. They will match these levels with tumour cell growth and death, aspirin usage, patient survival and tumour recurrence.

How will the molecule COMMD1 be studied?

The team have so far discovered that COMMD1 may be useful for identifying bowel cancer patients who will have a poorer prognosis, as well as those who would benefit from post-surgical therapy with aspirin.

They are collaborating with a team in Cuba who have identified a new drug called CIGB-552 that targets this molecule and has powerful activity against bowel cancer cells.

They are designing experiments to show how far COMMD1 drives the progression of cancer and how this can be affected by aspirin and CIGB-552. They believe that COMMD1 could be very important in cancer development and that being able to target the molecule could provide a new avenue for therapy.

The research team

This project is an exciting collaboration between Dr Lesley Stark at Edinburgh Cancer Research Centre and Dr Maribel Vallespi at the Centre of Genetic Engineering and Biotechnology of Cuba.

Why explore the molecule COMMD1’s role in bowel cancer?

This study has the potential to identify a biomarker for poor prognosis and how likely cancer is to recur. This is particularly important for stage II patients for whom no good biomarkers exist currently.

As well as this it may reveal a biomarker(s) for how a patient would respond to aspirin, which will allow doctors to identify patients who may benefit from taking aspirin, as well as provide useful information for clinical trials, such as Add-Aspirin, which is a large clinical trial looking at whether aspirin may stop or delay cancer recurrence.

Finally, it may reveal a new drug combination (aspirin and CIGB-552) for improved, targeted therapy in bowel cancer.

Final Report Summary

Many lines of evidence indicate aspirin use can prevent bowel cancer. However, this agent cannot be recommended for prevention purposes due to its side-effect profile. With funding from Bowel and Cancer Research, we have been investigating how aspirin acts against bowel cancer to identify patients who would benefit from aspirin therapy and targets for new anti-cancer drugs. We were particularly interested in a molecule in the cell called COMMD1, as our original data suggested that reduced levels of this molecule act as a marker for advanced tumour grade. They also suggested aspirin increases COMMD1 levels to kill bowel cancer cells.

Using arrays of small tumour sections from over 800 bowel cancer patients, we have confirmed that reduced levels of COMMD1 are an indicator of advanced cancer. Furthermore, we demonstrated for the first time that low tumour COMMD1 is associated with reduced survival. To undertake these studies, we developed an automated protocol for analysing COMMD1 levels in bowel tissue that will be invaluable for further research in this area and future clinical application.

Our collaborators in Cuba have identified an anti-tumour peptide called CIGB-552 that, like aspirin, acts by increasing levels of COMMD1. To determine whether aspirin and CIGB-552 have a greater effect against bowel cancer when used together, rather than alone, we treated mini mouse intestines grown in culture (organoids) with the agents. These studies revealed that both agents have a greater effect on cancer organoids than normal organoids, indicating cancer specificity. They also suggested that the growth inhibitory effects of the agents did not increase when used together. Alongside these studies, in collaboration with Innovate Pharmaceuticals, we tested a new formulation of aspirin and found that this is 10 times more effective at inhibiting the growth of cancer cells and organoids than standard aspirin. This is an extremely exciting new development and potential cancer treatment.

Together, these data confirm COMMD1 as an important molecule in bowel cancer prevention and a promising target for new therapies. The data have been presented at national and international meetings, including in Cuba. They have helped foster new relations between scientists from Cuba and Europe and facilitated a new collaboration with scientists working on Bowel cancer at the University of Cordoba. One paper has already been published that attracted considerable media attention, including television and radio appearances. Further data are being prepared for journal submission.

Impact of Bowel & Cancer Research funding

Bowel & Cancer Research funding has been invaluable to this project. It has allowed us to purchase all the consumables and has funded a member of staff who carried out the organoid studies and analysed the TMAs using QuPath. It also allowed us to complete the work leading to the seminal paper on aspirin and the nucleolus. Hence, we are extremely thankful.

Related Research

Help us fund more research like this. Make a donation